CGON icon

CG Oncology

24.17 USD
-0.01
0.04%
At close May 14, 4:00 PM EDT
After hours
24.17
+0.00
0.00%
1 day
-0.04%
5 days
6.71%
1 month
20.49%
3 months
-15.25%
6 months
-31.92%
Year to date
-16.57%
1 year
-11.53%
5 years
-34.97%
10 years
-34.97%
 

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

531% more call options, than puts

Call options by funds: $6.49M | Put options by funds: $1.03M

119% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 27

118% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 17

16% more funds holding

Funds holding: 121 [Q3] → 140 (+19) [Q4]

10.58% more ownership

Funds ownership: 77.79% [Q3] → 88.38% (+10.58%) [Q4]

9% more funds holding in top 10

Funds holding in top 10: 11 [Q3] → 12 (+1) [Q4]

3% less capital invested

Capital invested by funds: $1.96B [Q3] → $1.9B (-$67.1M) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$23
5%
downside
Avg. target
$56
132%
upside
High target
$75
210%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
JP Morgan
Brian Cheng
29% 1-year accuracy
5 / 17 met price target
70%upside
$41
Overweight
Initiated
2 May 2025
RBC Capital
Gregory Renza
22% 1-year accuracy
17 / 78 met price target
181%upside
$68
Outperform
Maintained
29 Apr 2025
Cantor Fitzgerald
Josh Schimmer
25% 1-year accuracy
14 / 55 met price target
210%upside
$75
Overweight
Reiterated
28 Apr 2025
HC Wainwright & Co.
Andres Maldonado
22% 1-year accuracy
11 / 51 met price target
210%upside
$75
Buy
Reiterated
28 Apr 2025
Scotiabank
5%downside
$23
Sector Perform
Initiated
16 Apr 2025

Financial journalist opinion

Based on 7 articles about CGON published over the past 30 days

Negative
Zacks Investment Research
1 day ago
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 day ago
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2025, and provided business updates.
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Negative
Zacks Investment Research
1 week ago
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Positive
Zacks Investment Research
2 weeks ago
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
Positive
Benzinga
2 weeks ago
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
Positive
Investors Business Daily
2 weeks ago
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Neutral
GlobeNewsWire
2 weeks ago
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
Positive
Seeking Alpha
1 month ago
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON's enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
Neutral
GlobeNewsWire
1 month ago
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Charts implemented using Lightweight Charts™